4D Molecular Therapeutics, Inc.

FDMT

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001650648

SEC filings (opens in a new tab)

In the last 90 days, 4D Molecular Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $771.2M in total; no superinvestor holds it.

Q4 2025 vs. Q3 2025

How the institutions holding 4D Molecular Therapeutics, Inc. changed between Q3 2025 and Q4 2025.

All holders in Q4 2025 All holders in Q3 2025

13F holders of FDMT: Q3 2025 compared with Q4 2025
Measure	Q3 2025	Of which not filed for Q4 2025	Q4 2025	Change
Holders	134	1	153	+20
Shares	39.5M	9.21K	53.4M	+13.9M (+35.1%)
Value	$343.2M	$80.1K	$400.5M	+$57.4M (+16.7%)

1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.

New holders (32)

Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.

Institutions new to FDMT in Q4 2025
Institution	Shares	Value	% of portfolio
Point72 Asset Management, L.P.	1,539,860	$11.5M	0.02%
Evergreen Quality Fund GP, Ltd.	951,474	$7.14M	0.14%
Baker Bros. Advisors LP	475,737	$3.57M	0.02%
RTW Investments, LP	475,737	$3.57M	0.04%
Burkehill Global Management, LP	275,000	$2.06M	0.14%
Woodline Partners LP	200,001	$1.50M	0.01%
Silverarc Capital Management, LLC	100,000	$750.0K	0.11%
Rafferty Asset Management, LLC	83,413	$625.6K	0.00%
Engineers Gate Manager LP	74,269	$557.0K	0.01%
Principia Wealth Advisory, LLC	53,668	$402.5K	0.25%
Walleye Capital LLC	50,762	$380.7K	0.00%
Jain Global LLC	40,464	$303.5K	0.00%
ExodusPoint Capital Management, LP	39,175	$293.8K	0.00%
Jump Financial, LLC	33,830	$253.7K	0.00%
Profund Advisors LLC	30,851	$231.4K	0.01%
Thrivent Financial for Lutherans	28,938	$217.0K	0.00%
Truist Financial Corp	25,000	$187.5K	0.00%
Virtus Investment Advisers, Inc.	24,541	$184.1K	0.05%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.	23,845	$174.5K	0.00%
EntryPoint Capital, LLC	22,324	$167.4K	0.07%
Commonwealth Equity Services, LLC	20,009	$150.1K	0.00%
Citadel Advisors LLC	19,889	$149.2K	0.00%
Landing Point Financial Group, LLC	19,000	$142.5K	0.07%
Polymer Capital Management (US) LLC	18,035	$135.3K	0.02%
SG Americas Securities, LLC	15,531	$116.0K	0.00%
Gabelli Funds LLC	12,000	$90.0K	0.00%
Susquehanna Portfolio Strategies, LLC	10,310	$77.3K	0.00%
Torren Management, LLC	2,361	$17.7K	0.01%
Caitong International Asset Management Co., Ltd	214	$1.60K	0.00%
Basecamp Wealth Advisors LLC	145	$1.09K	0.00%
Pinnacle Wealth Planning Services, Inc.	100	$750	0.00%
Sound Income Strategies, LLC	25	$189	0.00%

Sold out (12)

Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.

Institutions that sold out of FDMT in Q4 2025
Institution	Shares, Q3 2025	Value, Q3 2025
HSBC Holdings PLC	48,806	$403.6K
Capstone Investment Advisors, LLC	22,917	$199.1K
Proficio Capital Partners LLC	20,121	$174.9K
Zuckerman Investment Group, LLC	20,000	$173.8K
Brevan Howard Capital Management LP	16,400	$142.5K
Wexford Capital LP	4,676	$40.6K
Simplex Trading, LLC	2,925	$25.0K
Global Retirement Partners, LLC	1,500	$13.0K
Allworth Financial LP	393	$3.42K
US Bancorp	57	$495
Advisory Services Network, LLC	8	$70
Summit Wealth Group LLC	13,204	–

Not filed for Q4 2025 yet (1)

Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding FDMT in Q3 2025 that haven't filed for Q4 2025
Institution	Shares, Q3 2025	Value, Q3 2025
Abich Financial Wealth Management LLC	9,214	$80.1K